Literature DB >> 11342781

Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.

M Fujimura1, T Hidaka, K Kataoka, Y Yamakawa, S Akada, A Teranishi, S Saito.   

Abstract

The mechanism that regulates growth in ovarian clear cell adenocarcinoma (CCA) is not well understood. A high incidence of concurrent endometriosis with CCA may indicate that estrogen is a growth promotor in CCA. To determine estrogen as a growth promotor, the authors investigated the presence or absence of estrogen receptor-alpha (ER-alpha), ER-beta, progesterone receptor, and dioxin receptor (i.e., aromatic hydrocarbon receptor) in clinically resected ovarian CCA, serous adenocarcinoma (SAC), endometrioid adenocarcinoma (EAC), and mucinous adenocarcinoma (MAC) specimens using an immunohistochemical method. Expression of ER-alpha and ER-beta messenger ribonucleic acid was examined by reverse transcription-polymerase chain reaction in three established CCA cell lines: KK, RMG-1, and HAC-II. None of the surgically resected CCA and CCA cell lines showed positive staining for ER-alpha. Conversely, 97.2% of SACs, 100% of EACs, and 70% of MACs showed positive nuclear staining for ER-alpha (p < 0.001). Conversely, positive ER-beta staining for CCA (39.3%) was similar to that of SAC (41.7%) and MAC (30.0%). EAC (75%) showed a higher expression of ER-beta (p < 0.02). Progesterone receptor was detected in only 10.7% of CCA, compared with SAC and EAC (SAC, 86.1%; EAC, 91.7%; p < 0.01). Aromatic hydrocarbon receptor was detected in all histologic types at an incidence of approximately 50% to 60%. Messenger ribonucleic acid of ER-alpha and ER-beta was not detected in the three CCA cell lines. These findings indicate biologic characteristics that distinguish CCA from other types of ovarian epithelial cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342781     DOI: 10.1097/00000478-200105000-00016

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

Review 1.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.

Authors:  Gwendal Lazennec
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

2.  Epigenetic determinants of ovarian clear cell carcinoma biology.

Authors:  Ken Yamaguchi; Zhiqing Huang; Noriomi Matsumura; Masaki Mandai; Takako Okamoto; Tsukasa Baba; Ikuo Konishi; Andrew Berchuck; Susan K Murphy
Journal:  Int J Cancer       Date:  2014-01-14       Impact factor: 7.396

3.  Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.

Authors:  Wenbin Xiao; Amad Awadallah; Wei Xin
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

4.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Authors:  David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

5.  The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.

Authors:  Amy L Shafrir; Megan S Rice; Mamta Gupta; Kathryn L Terry; Bernard A Rosner; Rulla M Tamimi; Jonathan L Hecht; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2016-10-05       Impact factor: 5.482

Review 6.  Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.

Authors:  Dirkje W Sommeijer; Katrin M Sjoquist; Michael Friedlander
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

7.  Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

Review 8.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

Review 9.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

10.  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.

Authors:  Caroline H Diep; Nathan J Charles; C Blake Gilks; Steve E Kalloger; Peter A Argenta; Carol A Lange
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.